TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26746199
Drug: Professional fluoride
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional fluoride treatment (FVD) - 22,600 ppm F(−) varnish plus FD
Study: 11099368
Drug: Whole food
Normalized name: Concentrated Whole Food Multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole food (WF: protein 38 g; carbohydrate 70 g; fat 7 g)
Study: 24219166
Drug: Buprenorphine-naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone treatment for 12 weeks
Study: 18053393
Drug: Beta-blockers (atenolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (atenolol 100 mg id for five consecutive days)
Study: 16075416
Drug: Simvastatin and
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin and Atorvastatin
Study: 10229887
Drug: Peer Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer Assessment Rating (PAR) index treatment
Study: 8561152
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tetracycline 250 mg, metronidazole 250 mg, colloidal bismuth subcitrate 120 mg, four times daily for 14 days)
Study: 8561152
Drug: Amoxicillin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1000 mg) and omeprazole (40 mg) both twice daily for 14 days
Study: 8561152
Drug: Amoxicillin/omeprazole
Normalized name: AMOXICILLIN/OMEPRAZOLE/RIFABUTIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/omeprazole
Study: 6882885
Drug: Quinidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine administered with antacid
Study: 6882885
Drug: Quinidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine administered in fasting state
Study: 30869165
Drug: Perampanel 12
Normalized name: perampanel 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 12 mg
Study: 17371337
Drug: Doxazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4 mg/day)
Study: 20368567
Drug: Rituximab added
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab added to cyclophosphamide, doxorubicin, vincristine, and prednisone induction treatment
Study: 20368567
Drug: BCL2/IgH levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCL2/IgH levels at the end of induction treatment
Study: 9735662
Drug: Specific IgG
Normalized name: Mold specific IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgG antibodies
Study: 9735662
Drug: Specific IgG4
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgG4 antibodies
Study: 1099048
Drug: Doctor's Choice
Normalized name: Doctor's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doctor's Choice (DC) method of administering psychotropic drugs
Study: 1099048
Drug: Thioridazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (100 to 900 mg)
Study: 1099048
Drug: Chlordiazepoxide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (30 mg)
Study: 3088636
Drug: Imipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (75 mg)
Study: 29034602
Drug: Paracetamol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol alone (G-1)
Study: 20821332
Drug: Conservative standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative standard treatment (CST)
Study: 16315646
Drug: Complete case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete case analysis (CC)
Study: 1776351
Drug: Aqueous CO2
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous CO2 (succinate + sodium bicarbonate = Kao Bub; 1400 mg CO2 per kg water)
Study: 31899024
Drug: Topical Oxymetazoline
Normalized name: oxymetazoline Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Oxymetazoline
Study: 30732134
Drug: Tobramycin/dexamethasone ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin/dexamethasone ointment
Study: 18162137
Drug: 500 mcg
Normalized name: Nplate 500 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mcg fluticasone propionate twice daily
Study: 12418594
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of oral prednisolone (40 mg daily)
Study: 2137901
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g per day of 85 percent eicosapentaenoic and docosahexaenoic acids
Study: 24994571
Drug: SVV-based goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVV-based goal-directed therapy (GDT)
Study: 20837684
Drug: Topical salicylic
Normalized name: salicylic acid Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical salicylic acid self-application daily
Study: 28633147
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - 2 doses of 15 mg/kg intravenous TXA dissolved in 100 mL of saline, administered over 10 minutes; 1 dose before incision, 1 dose at wound closure.
Study: 28633147
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 100 mL of saline solution administered in a similar fashion to TXA.
Study: 25298165
Drug: Linagliptin and
Normalized name: linagliptin and empagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin and metformin combination therapy
Study: 21777700
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC)
Study: 9296318
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg, twice daily for 5 days)
Study: 16963663
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (subcutaneous administration)
Study: 12792378
Drug: cp‐45 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: cp‐45 vaccine
Study: 6281704
Drug: Intravenous Premarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Premarin
Study: 25779558
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus taxane therapy
Study: 25779558
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus taxane therapy
Study: 11402636
Drug: Community pharmacy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacy-based intervention including education on disease, pharmacotherapy, and self-management; inhalation technique assessment and correction.
Study: 9669459
Drug: X‐MS dragees
Approvals — FDA: no, EMA: no, PMDA: no
Description: X‐MS dragees (8 g X per day)
Study: 2658606
Drug: Weekly cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly cervical examinations and instruction regarding subtle symptoms and signs of preterm labor
Study: 11803730
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg/day
Study: 21163939
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 800 μg twice daily for 1 year
Study: 2412071
Drug: Ketanserin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin, 40 mg b.i.d. for 8 weeks
Study: 30517252
Drug: 1,600 mg
Normalized name: omega-3/dha/epa/fish oil 1,600 mg-500 mg-800 mg/5 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,600 mg of oral magnesium hydroxide through nasogastric (NG) tube prior to surgery
Study: 25733000
Drug: 6.0 mg
Normalized name: Dimethicone 6.0 mg in 30 mL TOPICAL CREAM [Clapiel Revital Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 mg pegfilgrastim
Study: 26423618
Drug: 6.0 mg
Normalized name: Dimethicone 6.0 mg in 30 mL TOPICAL CREAM [Clapiel Revital Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 mg pegteograstim
Study: 22674719
Drug: TEA +
Normalized name: Triethanolamine
DrugBank: Trolamine (DB13747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TEA + l‐NAME
Study: 20570110
Drug: Amisulpride (200-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (200-1000 mg) plus Celecoxib (400 mg)
Study: 20570110
Drug: Amisulpride (200-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (200-1000 mg) plus Placebo
Study: 12205570
Drug: High-dose salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose salmeterol (100 mcg, BID)
Study: 12205570
Drug: Albuterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2.5 mg, BID)
Study: 2358610
Drug: Diltiazem (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (270 mg/day)
Study: 17897926
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg/day)
Study: 7178
Drug: Bromazepam 6
Normalized name: bromazepam 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 6 mg t.i.d. during two weeks
Study: 15227625
Drug: High-dose alanyl-glutamine
Normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alanyl-glutamine
Study: 8339412
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of bamiphylline (5 mg/kg in 15 minutes)
Study: 25079049
Drug: Sonothrombolysis (transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonothrombolysis (transcranial Doppler monitoring plus intravenous tissue plasminogen activator)
Study: 24207098
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator alone
Study: 23156967
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy with energy dose of 52.5 J/cm2 (G-I)
Study: 10486696
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/day for 4 weeks
Study: 8759578
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac 60 mg
Study: 8759578
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IV ketorolac 60 mg and meperidine 50 mg
Study: 8759578
Drug: IV meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV meperidine 50 mg
Study: 1747501
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg once a day)
Study: 1747501
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg once a day)
Study: 31792640
Drug: Dotinurad 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotinurad 0.5 mg
Study: 31754882
Drug: Dotinurad 1
Normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dotinurad 1 mg
Study: 30806926
Drug: RC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC treatment
Study: 23812093
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment program (9 sessions)
Study: 21558576
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) solution 140 mg/kg
Study: 21558576
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 140 mg/kg
Study: 21558576
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) capsules (low doses)
Study: 11303007
Drug: Omacor 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor 2 g twice a day
Study: 19969286
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CBT)
Study: 16826026
Drug: L-carnitine L-tartrate
Normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine L-tartrate (LCLT) supplementation (2 g of L-carnitine per day)
Study: 1483879
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg epinephrine added to anesthetic solution
Study: 24336297
Drug: Triamcinolone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (8 mg, single injection followed by two sham interventions)
Study: 22314524
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g plus Aztreonam 1 g (V/A) q12h
Study: 17987533
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy of bladder cancer
Study: 12173299
Drug: Diphtheria toxoid
Normalized name: diphtheria toxoid
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria toxoid vaccine
Study: 10433584
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine
Study: 1176233
Drug: Decreasing dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreasing dose (N = 12)
Study: 29952075
Drug: In situ
Approvals — FDA: no, EMA: no, PMDA: no
Description: In situ photo‐immunotherapy (ISPI) with 808 nm laser irradiation
Study: 29952075
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod alone
Study: 28068786
Drug: Intrapericardial tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapericardial tranexamic acid 50 mg/kg in 20 mL of saline before sternal closure (Group B)
Study: 28068786
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravenous tranexamic acid 20 mg/kg after sternotomy and intrapericardial tranexamic acid 50 mg/kg before sternal closure (Group C)
Study: 23483571
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg carvedilol tablets
Study: 19453736
Drug: Emollient used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient used as maintenance therapy after topical corticotherapy
Study: 12434478
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid therapy
Study: 26589819
Drug: Lisinopril vs
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril vs Chlorthalidone
Study: 12352270
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg alone (medication management)
Study: 12853193
Drug: Carvedilol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (target dose 25 mg twice daily)
Study: 2616824
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg salbutamol via Rotacaps
Study: 2616824
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg salbutamol via Rotacaps
Study: 2616824
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg salbutamol via nebulizer
Study: 2616824
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg salbutamol via nebulizer
Study: 30879186
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (CTG)
Study: 15679494
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no mechanical bowel preparation)
Study: 14756852
Drug: Sumatriptan formulations
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan formulations (various routes of administration)
Study: 14756852
Drug: Placebo formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo formulations (matching sumatriptan formulations)
Study: 31826802
Drug: Paclitaxel micellar
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel micellar (250 mg/m2, 1-h infusion) + carboplatin (AUC 5-6)
Study: 31826802
Drug: Cr-EL paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cr-EL paclitaxel (175 mg/m2, 3-h infusion) + carboplatin (AUC 5-6)
Study: 25455873
Drug: Lidocaine (8.5-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (8.5-mL dose administered to the portio, cervix, and uterus)
Study: 9085313
Drug: Cefpodoxime 200
Normalized name: cefpodoxime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime 200 mg
Study: 9085313
Drug: Cefuroxime 500
Normalized name: cefuroxime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 500 mg
Study: 2393281
Drug: Cefprozil 500
Normalized name: cefprozil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil 500 mg
Study: 9085313
Drug: Loracarbef 400
Normalized name: loracarbef 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef 400 mg
Study: 29885994
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg intravenously every 2 weeks for 4 cycles)
Study: 29885994
Drug: Corticosteroids (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (methylprednisolone 500 mg/day intravenously for 3 days, then tapered, followed by 10 mg/day oral prednisone for 2 months)
Study: 16243240
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (preemptive, posttreatment, no-treatment)
Study: 2185965
Drug: 2% fenticonazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% fenticonazole spray
Study: 2185965
Drug: 1% cyclopyroxolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% cyclopyroxolamine spray
Study: 29244743
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of creatine nitrate (CNH)
Study: 29244743
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of creatine nitrate (CNL)
Study: 26617438
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of XAT and morphine (20 mg and 30 mg, respectively)
Study: 26617438
Drug: XAT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: XAT treatment
Study: 18214123
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg daily for eight weeks
Study: 18214123
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg daily for eight weeks
Study: 15259325
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of standard training for spatial scanning and optokinetic stimulation
Study: 15259325
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for spatial scanning
Study: 10929897
Drug: IgG serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG serum antibodies
Study: 26932169
Drug: SLIT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLIT plus vitamin D supplementation (1000 IU daily)
Study: 1974143
Drug: Propranolol LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol LA (160 mg)
Study: 1968912
Drug: Metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/ZOK (100 mg)
Study: 437431
Drug: β-sitosterol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-sitosterol (250 mg/kg/day)
Study: 437431
Drug: chenic acid
Normalized name: Chenic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chenic acid (10 mg/kg/day)
Study: 17374038
Drug: Naltrexone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone + Cognitive Behavioral Therapy (CBT)
Study: 17374038
Drug: Naltrexone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone + Motivational Enhancement Therapy (MET)
Study: 15353385
Drug: Galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 24 mg/day (12 mg bid)
Study: 9312920
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg
Study: 30833149
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) filler injection
Study: 30833149
Drug: Polylactic Acid
Normalized name: Polylactic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polylactic Acid (PLA) filler injection
Study: 28831752
Drug: Atrasentan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0.5 mg once daily for 8 weeks
Study: 28831752
Drug: Atrasentan 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 1.25 mg once daily for 8 weeks
Study: 22973945
Drug: Nurse-led intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led intervention including weekly nutrition and exercise education, exercise sessions, and nurse support (n = 51)
Study: 21301811
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin 10 IU
Study: 21301811
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin 20 IU
Study: 14731173
Drug: Hollow screw
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hollow screw (HS) implants
Study: 14731173
Drug: Hollow cylinder
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hollow cylinder (HC) implants
Study: 9208074
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 0.3 mg.kg‐1 with intravenous midazolam 2 mg
Study: 8355505
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose cytosine arabinoside (VLD-AC)
Study: 8355505
Drug: Low-dose aclarubicin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aclarubicin (LC-ACR)
Study: 3325317
Drug: split‐virion influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: split‐virion influenza vaccine (MFV‐Ject, Institut Merieux)